SG11201809726UA - Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist - Google Patents
Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonistInfo
- Publication number
- SG11201809726UA SG11201809726UA SG11201809726UA SG11201809726UA SG11201809726UA SG 11201809726U A SG11201809726U A SG 11201809726UA SG 11201809726U A SG11201809726U A SG 11201809726UA SG 11201809726U A SG11201809726U A SG 11201809726UA SG 11201809726U A SG11201809726U A SG 11201809726UA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- telangana
- hyderabad
- serene
- life sciences
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 4
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 4
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229960003530 donepezil Drugs 0.000 abstract 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract 2
- 229960004640 memantine Drugs 0.000 abstract 2
- 239000004783 Serene Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641017204 | 2016-05-18 | ||
PCT/IB2016/054672 WO2017199070A1 (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809726UA true SG11201809726UA (en) | 2018-12-28 |
Family
ID=56896730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809726UA SG11201809726UA (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Country Status (28)
Country | Link |
---|---|
US (1) | US11253514B2 (de) |
EP (1) | EP3458039B1 (de) |
JP (1) | JP6629464B2 (de) |
KR (1) | KR102016120B1 (de) |
CN (1) | CN109152751A (de) |
AU (1) | AU2016407426B2 (de) |
BR (1) | BR112018073410A2 (de) |
CA (1) | CA3023836C (de) |
CY (1) | CY1123644T1 (de) |
DK (1) | DK3458039T3 (de) |
EA (1) | EA038087B1 (de) |
ES (1) | ES2815555T3 (de) |
HK (1) | HK1258022A1 (de) |
HR (1) | HRP20201412T1 (de) |
HU (1) | HUE052077T2 (de) |
IL (1) | IL262920B (de) |
LT (1) | LT3458039T (de) |
MA (1) | MA45002B1 (de) |
MD (1) | MD3458039T2 (de) |
MX (1) | MX2018014184A (de) |
NZ (1) | NZ747797A (de) |
PL (1) | PL3458039T3 (de) |
PT (1) | PT3458039T (de) |
RS (1) | RS60849B1 (de) |
SG (1) | SG11201809726UA (de) |
SI (1) | SI3458039T1 (de) |
WO (1) | WO2017199070A1 (de) |
ZA (1) | ZA201807310B (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201913104QA (en) * | 2017-07-03 | 2020-01-30 | Suven Life Sciences Ltd | New uses of a pure 5-ht 6 receptor antagonist |
WO2021111320A1 (en) * | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Methods for treating behavioral and psychological symptoms in patients with dementia |
EP4069232A1 (de) | 2019-12-02 | 2022-10-12 | Suven Life Sciences Limited | Behandlung von verhaltens- und psychologischen symptomen bei demenzpatienten |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005528431A (ja) * | 2002-05-31 | 2005-09-22 | ハー・ルンドベック・アクチエゼルスカベット | アルツハイマー病を治療するためのnmda−アンタゴニスト及びアセチルコリンエステラーゼ阻害剤の組み合わせ物 |
ATE401307T1 (de) * | 2002-11-28 | 2008-08-15 | Suven Life Sciences Ltd | N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen |
KR101463190B1 (ko) * | 2010-01-05 | 2014-11-18 | 수벤 라이프 사이언시스 리미티드 | 5ht6 수용체 리간드인 술폰 화합물 |
RS56323B1 (sr) * | 2013-12-02 | 2017-12-29 | Suven Life Sciences Ltd | Proces za masovnu proizvodnju monohidrata 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1h-indol dimezilata |
US9840482B2 (en) * | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
-
2016
- 2016-08-03 CN CN201680085589.7A patent/CN109152751A/zh active Pending
- 2016-08-03 HU HUE16763575A patent/HUE052077T2/hu unknown
- 2016-08-03 MX MX2018014184A patent/MX2018014184A/es unknown
- 2016-08-03 MD MDE20190349T patent/MD3458039T2/ro unknown
- 2016-08-03 MA MA45002A patent/MA45002B1/fr unknown
- 2016-08-03 SI SI201630909T patent/SI3458039T1/sl unknown
- 2016-08-03 ES ES16763575T patent/ES2815555T3/es active Active
- 2016-08-03 NZ NZ747797A patent/NZ747797A/en unknown
- 2016-08-03 BR BR112018073410-1A patent/BR112018073410A2/pt not_active Application Discontinuation
- 2016-08-03 KR KR1020187035888A patent/KR102016120B1/ko active IP Right Grant
- 2016-08-03 SG SG11201809726UA patent/SG11201809726UA/en unknown
- 2016-08-03 US US16/097,752 patent/US11253514B2/en active Active
- 2016-08-03 WO PCT/IB2016/054672 patent/WO2017199070A1/en unknown
- 2016-08-03 DK DK16763575.4T patent/DK3458039T3/da active
- 2016-08-03 RS RS20201045A patent/RS60849B1/sr unknown
- 2016-08-03 CA CA3023836A patent/CA3023836C/en active Active
- 2016-08-03 PL PL16763575T patent/PL3458039T3/pl unknown
- 2016-08-03 LT LTEP16763575.4T patent/LT3458039T/lt unknown
- 2016-08-03 PT PT167635754T patent/PT3458039T/pt unknown
- 2016-08-03 EA EA201892528A patent/EA038087B1/ru unknown
- 2016-08-03 EP EP16763575.4A patent/EP3458039B1/de active Active
- 2016-08-03 AU AU2016407426A patent/AU2016407426B2/en active Active
- 2016-08-03 JP JP2018559327A patent/JP6629464B2/ja active Active
-
2018
- 2018-10-31 ZA ZA2018/07310A patent/ZA201807310B/en unknown
- 2018-11-11 IL IL262920A patent/IL262920B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100393.2A patent/HK1258022A1/zh unknown
-
2020
- 2020-09-03 HR HRP20201412TT patent/HRP20201412T1/hr unknown
- 2020-09-04 CY CY20201100834T patent/CY1123644T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201902886SA (en) | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201806424TA (en) | Therapeutic compounds | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201901070YA (en) | Formulations for oral administration of active agents | |
SG11201809726UA (en) | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist | |
SG11201809856SA (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
SG11201901999XA (en) | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making |